Clinical trial
Aralast alpha1-proteinase Inhibitor Surveillance Study
NCT00313144 · Baxalta now part of Shire, Industry · Terminated
Key facts
| NCT number | NCT00313144 |
|---|---|
| Title | Aralast alpha1-proteinase Inhibitor Surveillance Study |
| Official title | ARALAST alpha1-proteinase Inhibitor (α1-PI) Surveillance Study |
| Lead sponsor | Baxalta now part of Shire, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Alpha1-antitrypsin Deficiency |
| Intervention type | Drug |
| Interventions | ARALAST Alpha1-Proteinase Inhibitor |
| Enrollment | 127 |
| Start date | Jun 9, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | May 1, 2009 |
| First posted | Apr 12, 2006 |
| Last update posted | May 26, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: